Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » In Brief This Week: LineaRx, OncoCyte, Vela Diagnostics, CosmosID, More

In Brief This Week: LineaRx, OncoCyte, Vela Diagnostics, CosmosID, More

Feb 07, 2020
|
staff reporter

NEW YORK – Applied DNA Sciences subsidiary LineaRx said it has expanded an existing joint development agreement with Takis Biotech to include preclinical development of a linear DNA vaccine against 2019-nCoV, the novel coronavirus that originated in Wuhan, China.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Pause Recommended

The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.

Science and a Side of Diplomacy

According to the Associated Press, a Swiss program aims to shepherd long-term science projects and diplomacy.

New Studies of B.1.1.7

CNN reports that two new studies suggest the B.1.1.7 SARS-CoV-2 variant may be more transmissible, but may not lead to more severe disease.

PNAS Papers on Acute Kidney Injury, Parental Expression in Horse Placenta, Sea Urchin Microbes

In PNAS this week: analysis of pathway affecting acute kidney injury, parental-specific allelic expression in horse placenta, and more.

What's Popular?

In Business News

  1. Thermo Fisher Scientific Gets FDA EUA for High-Throughput, Automated COVID-19 Test Kit

  2. DiaSorin to Acquire Luminex for $1.8B

  3. Danaher Expects Q1 2021 Revenue Growth Above Previous Guidance

  4. Serimmune Launches Study Tracking Immune Response to SARS-CoV-2

  5. Congenica Strikes Asian Distribution Deal With Camtech Diagnostics

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.